Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease

Please always quote using this URN: urn:nbn:de:bvb:20-opus-117790
  • Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients previously considered as cured might present postglucose GH nadir levels not adequately suppressed, with potential implications on management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean follow-up period of 17.2 years from remission, inAcromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients previously considered as cured might present postglucose GH nadir levels not adequately suppressed, with potential implications on management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean follow-up period of 17.2 years from remission, in order to assess the impact of the current criteria. At the last follow-up visit, in the presence of normal IGF-I concentrations, postglucose GH nadir was over 0.4 mu g/L in 11 patients (Group A) and below 0.4 mu g/L in 29 patients (Group B); moreover, Group A showed higher basal GH levels than Group B, whereas a significant decline of both GH and postglucose GH nadir levels during the follow-up was observed in Group B only. No differences in other evaluated parameters were found. These results seem to suggest that acromegalic patients considered cured on the basis of previous guidelines do not need a more intensive monitoring than patients who met the current criteria of disease control, supporting instead that the cut-off of 0.4 mcg/L might be too low for the currently used GH assay.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Elisa Verrua, Emanuele Ferrante, Marcello Filopanti, Elena Malchiodi, Elisa Sala, Claudia Giavoli, Maura Arosio, Andrea Gerardo Lania, Christina Lucia Ronchi, Giovanna Mantovani, Paolo Beck-Peccoz, Anna Spada
URN:urn:nbn:de:bvb:20-opus-117790
Document Type:Journal article
Faculties:Medizinische Fakultät / Medizinische Klinik und Poliklinik I
Language:English
Parent Title (English):International Journal of Endocrinology
ISSN:1687-8345
Year of Completion:2014
Pagenumber:581594
Source:International Journal of Endocrinology Volume 2014, Article ID 581594, 8 p.. doi:10.1155/2014/581594
DOI:https://doi.org/10.1155/2014/581594
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:GH response; IGF-I; body mass index; diagnosis; glucose tolerance test; growth hormone deficiency; immunoassays; mortality; oral glucose; statement
Release Date:2015/08/24
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung